Pfizer Integrating Immunoaffinity Mass Spec into Drug Development Pipeline

The technique is useful for monitoring protein biomarkers in order to better understand target pathways and molecules as well building pharmacokinetic and pharmacodynamic models, said a company scientist.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.